Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03056755
Title	Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (BYLieve)
Acronym	BYLieve
Recruitment	Active, not recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Novartis Pharmaceuticals
Indications	Her2-receptor negative breast cancer
Therapies	Alpelisib + Fulvestrant Alpelisib + Letrozole
Age Groups:	adult \| senior
Covered Countries	USA \| NLD \| ITA \| ISR \| GBR \| FRA \| ESP \| DNK \| DEU \| CAN \| BEL \| ARG